Dubberke Erik R, Reske Kimberly A, Olsen Margaret A, Bommarito Kerry M, Seiler Sondra, Silveira Fernanda P, Chiller Tom M, DiPersio John, Fraser Victoria J
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO.
Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA.
Transplant Direct. 2017 Mar 17;3(4):e145. doi: 10.1097/TXD.0000000000000662. eCollection 2017 Apr.
infection (CDI) is a frequent cause of diarrhea among allogeneic hematopoietic cell transplant (HCT) recipients. It is unknown whether risk factors for CDI vary by time posttransplant.
We performed a 3-year prospective cohort study of CDI in allogeneic HCT recipients. Participants were enrolled during their transplant hospitalizations. Clinical assessments were performed weekly during hospitalizations and for 12 weeks posttransplant, and monthly for 30 months thereafter. Data were collected through patient interviews and chart review, and included CDI diagnosis, demographics, transplant characteristics, medications, infections, and outcomes. CDI cases were included if they occurred within 1 year of HCT and were stratified by time from transplant. Multivariable logistic regression was used to determine risk factors for CDI.
One hundred eighty-seven allogeneic HCT recipients were enrolled, including 63 (34%) patients who developed CDI. 38 (60%) CDI cases occurred during the preengraftment period (days 0-30 post-HCT) and 25 (40%) postengraftment (day >30). Lack of any preexisting comorbid disease was significantly associated with lower risk of CDI preengraftment (odds ratio [OR], 0.3; 95% confidence interval [CI], 0.1-0.9). Relapsed underlying disease (OR, 6.7; 95% CI, 1.3-33.1), receipt of any high-risk antimicrobials (OR, 11.8; 95% CI, 2.9-47.8), and graft-versus-host disease (OR, 7.8; 95% CI, 2.0-30.2) were significant independent risk factors for CDI postengraftment.
A large portion of CDI cases occurred during the postengraftment period in allogeneic HCT recipients, suggesting that surveillance for CDI should continue beyond the transplant hospitalization and preengraftment period. Patients with continued high underlying severity of illness were at increased risk of CDI postengraftment.
艰难梭菌感染(CDI)是异基因造血细胞移植(HCT)受者腹泻的常见原因。CDI的危险因素是否随移植后时间而变化尚不清楚。
我们对异基因HCT受者的CDI进行了一项为期3年的前瞻性队列研究。参与者在移植住院期间入组。住院期间每周进行临床评估,移植后12周内每周评估,此后30个月每月评估。通过患者访谈和病历审查收集数据,包括CDI诊断、人口统计学、移植特征、药物治疗、感染和结局。如果CDI病例发生在HCT后1年内,则纳入研究,并按移植后的时间进行分层。采用多变量逻辑回归确定CDI的危险因素。
共纳入187例异基因HCT受者,其中63例(34%)发生CDI。38例(60%)CDI病例发生在植入前期(HCT后0-30天),25例(40%)发生在植入后期(>30天)。移植前无任何合并症与较低的CDI风险显著相关(优势比[OR],0.3;95%置信区间[CI],0.1-0.9)。潜在疾病复发(OR,6.7;95%CI,1.3-33.1)、接受任何高风险抗菌药物(OR,11.8;95%CI,2.9-47.8)和移植物抗宿主病(OR,7.8;95%CI,2.0-30.2)是植入后CDI的显著独立危险因素。
异基因HCT受者中很大一部分CDI病例发生在植入后期,这表明对CDI的监测应持续到移植住院期和植入前期之后。疾病严重程度持续较高的患者植入后发生CDI的风险增加。